The Upjohn pharmaceutical company was started by William Erastus Upjohn in 1885 and was a research and industry pillar in Kalamazoo until its merger with the Swedish company Pharmacia in 1995. The hybrid company was bought by Pfizer in 2003.

https://web.archive.org/web/20200405200549/https://web.archive.org/web/20070928141332/http://www.kpl.gov/collections/LocalHistory/AllAbout/biography/Upjohn.aspx

In 1952 two Upjohn biochemists, Dury Peterson and Herb Murray announced that they were able to introduce this crucial oxygen atom by fermentation of the steroid progesterone with the mold Aspergillus nigercans. Over the next several years a group of chemists headed by John Hogg developed a process for preparing cortisone from the soybean steroid stigmasterol. The microbiological oxygenation is a key step in this process. Monsanto was part of the acquisition and divesting scheme at Pfiser and ties to the soy interest.

https://web.archive.org/web/20110205152913/http://en.wikipedia.org/wiki/Upjohn

2007 NEW YORK, Jan. 19 /PRNewswire-FirstCall/ – Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) today announced the completion of its acquisition of Embrex, Inc. (Nasdaq: EMBX), an international agricultural biotechnology company.

Embrex, Inc., headquartered in Research Triangle Park, is an international agricultural bio-technological company founded in 1985. The facility will manufacture Embrex's Inovocox, a vaccine to prevent coccidiosis, a parasitic disease that afflicts birds' digestive systems. The vaccine is delivered to chicks before they are hatched via Embrex's Inovoject automated egg injection system.

Embrex, Inc., the Inovo Company™, held a ribbon-cutting ceremony in March with Gov. Mike Easley to commemorate the opening of a “first of its kind” biological manufacturing facility in Laurinburg, N.C. Embrex Poultry Health will use the facility to produce its novel Inovocox™ in ovo coccidiosis vaccine upon approval from the U.S. Department of Agriculture.

The plant's vaccine will be ready for Food and Drug Administration approval in 2005. Approval is expected, and the plant will begin production for sale in late 2005.

https://web.archive.org/web/20061010002836/http://www.ncbiotech.org/news_and_events/industry_news/embrex_opens_biomanufacturing_plant.html

Its growth continued in 2004 with a 17.2 percent increase in agency billings. Growth came from Rhea & Kaiser’s three largest clients, Bayer CropScience, Pfizer Animal Health and Caterpillar Inc. Pfizer Animal Health awarded the agency its REVOLUTION® (Selamectin) parasiticide business in 2003, and RIMADYL® (Carprofen) and Anti-infectives businesses in 2004. All work for Bayer CropScience, Pfizer Animal Health and Caterpillar are integrated advertising and public relations communication assignments. https://web.archive.org/web/20050707084627/http://www.rkconnect.com/news.asp?newsID=43

The Pfizer-BioNTech COVID-19 vaccine is an mRNA gene therapy-based COVID-19 vaccine product developed by Pfizer and BioNTech.

The Pfizer-BioNTech was approved for use in Canada under the name Comirnaty for individuals as young as 12 years old. The active ingredient is listed as “Tozinameran (mRNA encoding the Spike protein for the SARS-CoV-2 virus)”. ¹⁾

https://twitter.com/9thfloor/status/1444636724672536576?s=20

https://twitter.com/Covid19Crusher/status/1450341870438133762?s=20

https://twitter.com/Mind_gone_One/status/1450482329466458125?s=20

https://twitter.com/indepdubnrth/status/1455879620318965763?s=20